1. Mesothelin-targeted bispecific antibodies drive synthetic agonistic receptor – Transduced T cells to mediate specific and conditional therapy of human pancreatic cancer models. (March 2018) Authors: Benmebarek, M.; Karches, C.; Schmidbauer, M.; Kurzay, M.; Klaus, R.; Geiger, M.; Rataj, F.; Cadilha, B.; Keyl, J.; Lesch, S.; Heise, C.; Murr, R.; vom Berg, J.; Jastroch, M.; Lamp, D.; Niederfellner, G.; Sustmann, C.; Endres, S.; Klein, C.; Kobold, S. Journal: European journal of cancer Issue: Volume 92(2018)Supplement 1 Page Start: S20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Proof of concept and mode of action of a novel modular platform for adoptive T cell therapy combining bispecific antibodies with synthetic agonistic receptors. (March 2018) Authors: Karches, C.; Benmebarek, M.; Schmidbauer, M.; Kurzay, M.; Klaus, R.; Geiger, M.; Lesch, S.; Cadilha, B.; Rataj, F.; Heise, C.; Murr, R.; vom Berg, J.; Jastroch, M.; Lamp, D.; Duewell, P.; Niederfellner, G.; Sustmann, C.; Endres, S.; Klein, C.; Kobold, S. Journal: European journal of cancer Issue: Volume 92(2018)Supplement 1 Page Start: S19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗